

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vignia 22313-1450 www.uspto.gov

09/445,201	04/12/2000			
	04/12/2000	Georg Breier	VOSS1110	9638
7590	06/20/2003			
LISA A. HAILE, Ph		EXAMINER		
GARY CARY WARE 4365 Executive Drive.		SULLIVAN, DANIEL M		
Suite 1100			ART UNIT	PAPER NUMBER
San Diego, CA 9212	1-2133		1636	29

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)
		09/445,201	BREIER ET AL.
	Office Action Summary	Examiner	Art Unit
		Daniel M Sullivan	1636
Period fo	The MAILING DATE of this communication	appears on the cover s	heet with the correspondence address
A SH THE I - Exter after - If the - If NC - Failu - Any r	ORTENED STATUTORY PERIOD FOR REMAILING DATE OF THIS COMMUNICATIOnsions of time may be available under the provisions of 37 CF SIX (6) MONTHS from the mailing date of this communication period for reply specified above is less than thirty (30) days, a period for reply is specified above, the maximum statutory period for reply within the set or extended period for reply will, by sieply received by the Office later than three months after the modern adjustment. See 37 CFR 1.704(b).	DN. R 1.136(a). In no event, howeve the reply within the statutory minimum riod will apply and will expire SIX atute. Cause the application to be	r, may a reply be timely filed um of thirty (30) days will be considered timely. (6) MONTHS from the mailing date of this communication.
1)🖂	Responsive to communication(s) filed on	05 June 2003 .	
2a)[This action is non-fina	I.
3) Dispositi		owance except for form	nal matters, prosecution as to the merits is
4)🖂	Claim(s) <u>1-11,13,17-23 and 42-44</u> is/are p	ending in the applicatio	n.
	4a) Of the above claim(s) is/are with	drawn from consideration	on.
	Claim(s) is/are allowed.		
6)⊠	Claim(s) <u>1-11,13,17-23 and 42-44</u> is/are re	ected.	
7)	Claim(s) is/are objected to.		
8)[Claim(s) are subject to restriction an	d/or election requireme	ent.
	on Papers	·	
9)[] 7	he specification is objected to by the Exam	iner.	
10)[] 1	he drawing(s) filed on is/are: a)□ ad	ccepted or b) objected	to by the Examiner.
_	Applicant may not request that any objection to	the drawing(s) be held in	abeyance. See 37 CFR 1.85(a).
11)∐ T	he proposed drawing correction filed on		o) disapproved by the Examiner.
	If approved, corrected drawings are required in		
	he oath or declaration is objected to by the	Examiner.	
Priority u	nder 35 U.S.C. §§ 119 and 120		
13) 🗌	Acknowledgment is made of a claim for fore	eign priority under 35 U	S.C. § 119(a)-(d) or (f).
a)[☐ All b)☐ Some * c)☐ None of:	•	
	1. Certified copies of the priority docume	ents have been receive	d.
:	2. Certified copies of the priority docume	ents have been receive	d in Application No
	 Copies of the certified copies of the p application from the International see the attached detailed Office action for a l 	Bureau (PCT Rule 17.2	?(a))
14) 🗌 Ad	knowledgment is made of a claim for dome	estic priority under 35 U	S.C. § 119(e) (to a provisional application).
a)	The translation of the foreign language cknowledgment is made of a claim for dome	provisional application	nas been received.
Notice Notice Information	of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PTO-948) ation Disclosure Statement(s) (PTO-1449) Paper No(s	5) No	erview Summary (PTO-413) Paper No(s) ice of Informal Patent Application (PTO-152) er: .
. Patent and Trac O-326 (Rev.	04.04)	Action Summary	Part of Paper No. 29

Art Unit: 1636

DETAILED ACTION

This Office Action is a response to the "Supplemental Amendment..." filed 5 June 2003 (Paper No. 29) in reply to the Final Office Action mailed 23 April 2002 (Paper No. 23). Claims 12, 15, 16, 25-33 and 36-41 have been withdrawn from consideration. Claims 1-11, 13, 14, 17-23 and 42-44 were considered in Paper No. 23. Claims 12, 14-16, 25-33 and 36-41 were canceled and claims 1, 3, 9 and 13 were amended in Paper No. 29. Claims 1-11, 13, 17-23 and 42-44 are pending and under consideration.

Response to Amendment

Rejection of claims 1-11, 13, 17-23 and 42-44 under 35 U.S.C. §112, first paragraph, as lacking adequate written description is withdrawn in view of the amendments to the claims in Paper No. 29.

New Grounds

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-11, 13, 17-23 and 42-44 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled

Art Unit: 1636

in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Vas-Cath Inc. v. Mahurkar, 19USPQ2d 1111, clearly states that "applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession *of the invention*. The invention is, for purposes of the 'written description' inquiry, *whatever is now claimed*." (See page 1117.) The specification does not "clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed." (See *Vas-Cath* at page 1116).

In the instant case, claims 1 (part (iii)), 3 (part (c)) and 9 (part (c)), and all claims depending therefrom are directed to a DNA comprising a fragment of a nucleotide sequence which comprises a disclosed nucleotide sequence. Because the claims are directed to a fragment of a nucleic acid containing both disclosed and undisclosed sequence, the claimed nucleic acid encompasses a genus of nucleic acids having no structural limitation (i.e., comprising a fragment of the undisclosed sequence). For example, Applicant's claims encompass any and all fragments of the chromosome comprising SEQ ID NO: 1 which has the function of conferring expression in endothelial cells *in vivo*. In this case, the claimed subject matter is described solely by function with no corresponding structural characteristic. An adequate written description of a DNA requires more than a mere statement that it is part of the invention and reference to a potential method for isolating it; what is required is a description of the DNA itself. It is not sufficient to define DNA solely by its principal biological property, i.e., it confers expression in endothelial cells *in vivo*, because disclosure of no more than that, as in the instant case, is simply a wish to know the identity of any DNA with that biological property. Also, naming a type of material

Art Unit: 1636

generically known to exist, in the absence of knowledge as to what that material consists of, is not a description of that material. Thus, claiming all DNA's that achieve a result without defining what means will do is not in compliance with the description requirement. Rather, it is an attempt to preempt the future before it has arrived. (See *Fiers v. Revel*, 25 USPQ2d 1601 (CA FC 1993) and *Regents of the Univ. Calif. v. Eli Lilly & Co.*, 43 USPQ2d 1398 (CA FC, 1997)).

In view of these considerations, a skilled artisan would not have viewed the teachings of the specification as sufficient to show that the applicant was in possession of the claimed invention commensurate to its scope because it does not provide adequate written description for the broad class of *any* and *all* fragments of a nucleotide sequence capable of conferring expression in endothelial cells *in vivo*. Applicant could overcome this rejection by rewriting the claims such that the fragment comprised within the nucleic acid were limited to <u>consisting of</u> a portion of a disclosed nucleic acid sequence.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 7 and 8 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 7 is indefinite in being directed to a DNA molecule comprising a promoter wherein the promoter is a promoter of hypoxia inducible genes, etc. It is unclear how the claim should be limited in view of the use of the plural. For example, must the promoter be found in more than one gene to be encompassed by the claim? It is recommended that the singular be used

Art Unit: 1636

Page 5

to describe the promoter to indicate that the promoter is found in at least one gene, if that is what Applicant intends.

Claim 8 is indefinite insofar as it depends from claim 7.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Daniel M Sullivan whose telephone number is 703-305-4448. The examiner can normally be reached on Monday through Friday 8-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Remy Yucel, Ph.D. can be reached on 703-305-1998. The fax phone numbers for the organization where this application or proceeding is assigned are 703-746-9105 for regular communications and 703-746-9105 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

dms

June 19, 2003

JAMES KETTER
PRIMARY EXAMINER